The Conversation (0)
BrainStorm Cell Therapeutics (OTCQB:BCLI) has been granted Patent No. 8,647,874, an additional patent for its autologous stem cell technology by the U.S. Patent and Trademark Office.
BrainStorm Cell Therapeutics (OTCQB:BCLI) has been granted Patent No. 8,647,874, an additional patent for its autologous stem cell technology by the U.S. Patent and Trademark Office.
As quoted in the press release:
The patent (No. 8,647,874) covers the production method of the company’s proprietary stem cells induced to secrete significantly elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases.
Click here to read the BrainStorm Cell Therapeutics (OTCQB:BCLI) press release
